Title of article
Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome
Author/Authors
Xin Gu، نويسنده , , Jasminka Dragovic، نويسنده , , Gloria C. Koo، نويسنده , , Sam L. Koprak، نويسنده , , Cheryl LeGrand، نويسنده , , Steven S. Mundt، نويسنده , , Kashmira Shah، نويسنده , , Marty S. Springer، نويسنده , , Eugene Y. Tan، نويسنده , , Rolf Thieringer، نويسنده , , Anne Hermanowski-Vosatka، نويسنده , , Hratch J. Zokian، نويسنده , , James M. Balkovec، نويسنده , , Sherman T. Waddell، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
4
From page
5266
To page
5269
Abstract
Replacement of the pentyl chain on our original bicyclo[2.2.2]octyltriazole leads 1 and 2 has led to the discovery that heteroaryl substituted bicyclo[2.2.2]octyltriazoles are potent and selective 11β-hydroxysteroid dehydrogenase type I (11β-HSD1) inhibitors with excellent pharmacokinetic profiles.
Keywords
11?-Hydroxysteroid dehydrogenase type I , 11?-HSD1 , 11?-HSD2 , glucocorticoids , Cortisone , cortisol , Heterocycle , Oxadiazole , triazole , Pharmacokinectics , Pharmacodynamic assay , Metabolic syndrome , imidazole
Journal title
Bioorganic & Medicinal Chemistry Letters
Serial Year
2005
Journal title
Bioorganic & Medicinal Chemistry Letters
Record number
796170
Link To Document